Business
US product launch of LPLDL® at trade show
US product launch of LPLDL® at trade show.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \nRNS Number : 8198O OptiBiotix Health PLC 24 August 2017 \n\nOptiBiotix Health plc\n(\"OptiBiotix\" or the \"Company\")\nUS product launch of LPLDL® at Supply Side West trade show\nOptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it plans for a US launch of LPLDL®, its cholesterol and blood pressure lowering product, at Supply Side West in Las Vegas, on 27-28 September 2017. This follows the global manufacturing and supply agreement with Sacco S.r.l. (\"Sacco\") announced on 22 August 2017.\n \nThe Supply Side West tradeshow brings together more than 15,000 ingredient buyers and suppliers from the supplement, beverage, functional food, personal care and sports nutrition industries and is viewed as one of the world's leading trade fairs for the food and drinks industry.\nOptiBiotix will co-exhibit with Sacco and will present new product concepts, as well as launching existing products containing its cholesterol reducing strain (LPLDL®) at the show, including:-\n· CholBiome®: a proprietary formulation containing LPLDL® to reduce cholesterol levels and blood pressure; and\n· CardioBiome®: a proprietary formulation containing LPLDL® to reduce a wide range of cardiovascular disease factors and improve long term heart health.\nThe US launch of LPLDL®, CholBiome® and CardioBiome® at Supply Side West is the first of a number of commercial steps taken to supply LPLDL® to food, beverage, consumer healthcare and pharmaceutical partners to be incorporated into final formulations and presentations for distribution and sale into the US market.\n \nThe US is one of the largest and fastest-growing probiotic markets in the world, with supplements alone accounting for US$2.06bn sales, with a projected 55% growth to US$3.3bn by 2021. Discussions continue to progress with corporate partners for the manufacture and distribution of products containing LPLDL® in the European, Asian and other international markets.\n \nStephen O'Hara, CEO of OptiBiotix, commented: \"OptiBiotix has made significant progress in raising industry awareness of its LPLDL® strain. This has created a high level of interest in commercialising products containing LPLDL® as a component in ...